Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CK Life Sciences International (Holdings), Inc. ( (HK:0775) ) has provided an update.
CK Life Sciences’ subsidiary Sequencio Therapeutics will present preclinical data from its cancer vaccine pipeline at the AACR Annual Meeting 2026 in San Diego, marking its first major scientific showcase. The five abstracts cover investigational vaccines targeting p53 neoantigen, IGF1R, B7-H3, TROP2 and Claudin 6, all designed using Sequencio’s proprietary TrueHLA Epitope-to-Efficacy framework across circRNA, mRNA, peptide and protein platforms.
The preclinical results highlight robust immunogenicity and anti-tumour activity across multiple targets and modalities, underscoring the strength of Sequencio’s rational, data-driven approach to vaccine design. Building on these findings, the company is prioritising its most promising programmes for IND-enabling studies and aims to advance selected candidates into early-stage clinical development via strategic partnerships, while cautioning investors that all work remains at the preclinical stage with no assurance of eventual clinical success.
The most recent analyst rating on (HK:0775) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on CK Life Sciences International (Holdings), Inc. stock, see the HK:0775 Stock Forecast page.
More about CK Life Sciences International (Holdings), Inc.
CK Life Sciences International (Holdings) Inc. is a biotechnology company focused on life science research and innovation, including advanced therapeutic platforms in oncology. Through subsidiaries such as Sequencio Therapeutics, the group is expanding into next-generation cancer vaccines aimed at global markets for cutting-edge immuno-oncology treatments.
Average Trading Volume: 7,933,920
Technical Sentiment Signal: Hold
Current Market Cap: HK$6.34B
See more data about 0775 stock on TipRanks’ Stock Analysis page.